Updated : 26 Aug 2021
Oops! Something went wrong while submitting the form.
03_speaker_img4
Laura M Cha
Chairman, HKEX

Mrs Cha is Chairman of Hong Kong Exchanges and Clearing Ltd and a member of the Executive Council of the Government of Hong Kong.

Mrs Cha is also a Non-Executive Director of Unilever plc, a Senior International Advisor of Foundation Assets Management Sweden AB and a member of Sotheby’s International Advisory Board. In addition, she is also Vice Chairman of the International Advisory Council of the China Securities Regulatory Commission, and a Director of the World Federation of Exchanges.

Mrs Cha became the first, and to-date, the only person outside Mainland China to join the Central Government of the People’s Republic of China at the vice ministerial rank when she was appointed as Vice Chairman of the China Securities Regulatory Commission in January 2001. She served in that position until September 2004. Mrs Cha worked for the Securities and Futures Commission in Hong Kong from 1991 to 2000, becoming its Deputy Chairman in 1998. She was also Chairman of The Financial Services Development Council of Hong Kong from January 2013 to July 2018.

She was awarded a Silver Bauhinia Star in 2001, a Gold Bauhinia Star in 2009 and the Grand Bauhinia Medal in 2017 by the Hong Kong Government for her public service.


Mrs Cha is Chairman of Hong Kong Exchanges and Clearing Ltd and a member of the Executive Council of the Government of Hong Kong.

Mrs Cha is also a Non-Executive Director of Unilever plc, a Senior International Advisor of Foundation Assets Management Sweden AB and a member of Sotheby’s International Advisory Board. In addition, she is also Vice Chairman of the International Advisory Council of the China Securities Regulatory Commission, and a Director of the World Federation of Exchanges.

Mrs Cha became the first, and to-date, the only person outside Mainland China to join the Central Government of the People’s Republic of China at the vice ministerial rank when she was appointed as Vice Chairman of the China Securities Regulatory Commission in January 2001. She served in that position until September 2004. Mrs Cha worked for the Securities and Futures Commission in Hong Kong from 1991 to 2000, becoming its Deputy Chairman in 1998. She was also Chairman of The Financial Services Development Council of Hong Kong from January 2013 to July 2018.

She was awarded a Silver Bauhinia Star in 2001, a Gold Bauhinia Star in 2009 and the Grand Bauhinia Medal in 2017 by the Hong Kong Government for her public service.


Read More...
Read Less
aguzin
Nicolas Aguzin
Chief Executive Officer, HKEX

Nicolas Aguzin joined HKEX as Chief Executive Officer on 24 May 2021 from J.P. Morgan, where he was most recently Chief Executive Officer of J.P. Morgan’s International Private Bank. Mr Aguzin has been based in Hong Kong since 2012.

From 2013 to 2020, Mr Aguzin was CEO, J.P. Morgan, Asia Pacific where he was responsible for all the firm’s business across 17 markets. Mr Aguzin presided over some of the firm’s major expansion efforts during the period, including establishing itself in China as one of the few international financial institutions with a full range of services and capabilities; including a fully-owned locally incorporated commercial bank, a majority-owned securities company, an asset management company and a futures and options company. Concurrent with his Asia CEO role, Mr Aguzin also ran J.P. Morgan’s Investment Banking division in Asia. During his tenure the bank rose to become one of the leading investment banks in the Asia Pacific region.

Mr Aguzin joined J.P. Morgan in 1990 in Buenos Aires as a financial analyst. Between 1990 and 2005, he held a variety of roles in New York and Buenos Aires, and in 2005 he was appointed as CEO, Latin America. In 2008 and 2009, in addition to his responsibilities as CEO, Latin America and Head of Latin America Investment Banking, he served as Senior Country Officer for Brazil.

Mr Aguzin holds a bachelor degree in Economics from the Wharton School of the University of Pennsylvania in the U.S. and is fluent in Spanish, Portuguese and English.

Nicolas Aguzin joined HKEX as Chief Executive Officer on 24 May 2021 from J.P. Morgan, where he was most recently Chief Executive Officer of J.P. Morgan’s International Private Bank. Mr Aguzin has been based in Hong Kong since 2012.

From 2013 to 2020, Mr Aguzin was CEO, J.P. Morgan, Asia Pacific where he was responsible for all the firm’s business across 17 markets. Mr Aguzin presided over some of the firm’s major expansion efforts during the period, including establishing itself in China as one of the few international financial institutions with a full range of services and capabilities; including a fully-owned locally incorporated commercial bank, a majority-owned securities company, an asset management company and a futures and options company. Concurrent with his Asia CEO role, Mr Aguzin also ran J.P. Morgan’s Investment Banking division in Asia. During his tenure the bank rose to become one of the leading investment banks in the Asia Pacific region.

Mr Aguzin joined J.P. Morgan in 1990 in Buenos Aires as a financial analyst. Between 1990 and 2005, he held a variety of roles in New York and Buenos Aires, and in 2005 he was appointed as CEO, Latin America. In 2008 and 2009, in addition to his responsibilities as CEO, Latin America and Head of Latin America Investment Banking, he served as Senior Country Officer for Brazil.

Mr Aguzin holds a bachelor degree in Economics from the Wharton School of the University of Pennsylvania in the U.S. and is fluent in Spanish, Portuguese and English.

Read More...
Read Less
Neil Shen photo
Neil Shen
Founding & Managing Partner, Sequoia Capital China

Mr Neil Shen is Steward of Sequoia Capital, and Founding & Managing Partner of Sequoia Capital China. He is also Co-Founder of Trip.com (NASDAQ: TCOM) and Homeinns Hotel Group (NASDAQ: HMIN).

Mr Shen has received numerous honours and awards in China and across the globe. He continues to hold the top position in the Forbe’s Midas List 2020, having reached the top of The Midas List 2018 - the first time a Chinese national made it to the top of the list. He is also listed in the "100 Greatest Living Business Minds" by Forbes. In addition, he was listed on the "50 Most Influential Business Leaders in China" and "30 Most Influential Investors in China" by Fortune from 2015 to 2020, and placed within the "Top 20 Venture Capitalists Worldwide" by New York Times and CB Insights from 2016 to 2019.

Mr Shen serves a number of philanthropic and public organisations and industry associations, including as Vice Chairman of the VC Funds Committee of Asset Management Association of China, Member of the Hong Kong Chief Executive’s Council of Advisors on Innovation and Strategic Development, Member of HKEX International Advisory Council, Chairman of Yale Center Beijing Executive Council, Trustee of Shanghai Jiao Tong University, Director of Yabuli China Entrepreneur Forum (CEF).

He received his Master's degree from Yale University and Bachelor's degree from Shanghai Jiao Tong University.

 


Mr Neil Shen is Steward of Sequoia Capital, and Founding & Managing Partner of Sequoia Capital China. He is also Co-Founder of Trip.com (NASDAQ: TCOM) and Homeinns Hotel Group (NASDAQ: HMIN).

Mr Shen has received numerous honours and awards in China and across the globe. He continues to hold the top position in the Forbe’s Midas List 2020, having reached the top of The Midas List 2018 - the first time a Chinese national made it to the top of the list. He is also listed in the "100 Greatest Living Business Minds" by Forbes. In addition, he was listed on the "50 Most Influential Business Leaders in China" and "30 Most Influential Investors in China" by Fortune from 2015 to 2020, and placed within the "Top 20 Venture Capitalists Worldwide" by New York Times and CB Insights from 2016 to 2019.

Mr Shen serves a number of philanthropic and public organisations and industry associations, including as Vice Chairman of the VC Funds Committee of Asset Management Association of China, Member of the Hong Kong Chief Executive’s Council of Advisors on Innovation and Strategic Development, Member of HKEX International Advisory Council, Chairman of Yale Center Beijing Executive Council, Trustee of Shanghai Jiao Tong University, Director of Yabuli China Entrepreneur Forum (CEF).

He received his Master's degree from Yale University and Bachelor's degree from Shanghai Jiao Tong University.

 


Read More...
Read Less
Jennifer Doudna
Jennifer Doudna
Biochemist and Nobel Prize winning co-inventor of CRISPR technology

Jennifer Doudna, PhD is a biochemist at the University of California, Berkeley. Her groundbreaking development of CRISPR-Cas9 - a genome engineering technology that allows researchers to edit DNA - with collaborator Emmanuelle Charpentier earned the two the 2020 Nobel Prize in Chemistry and forever changed the course of human and agricultural genomics research. She is also the founder and President of the Innovative Genomics Institute, the Li Ka Shing chancellor’s chair in Biomedical and Health Sciences, and a member of the Howard Hughes Medical Institute, Lawrence Berkeley National Lab, Gladstone Institutes, the National Academy of Sciences, and the American Academy of Arts and Sciences. She is a leader in the global public debate on the responsible use of CRISPR and has co-founded and serves on the advisory panel of several companies that use the technology in unique ways. Dr Doudna is the co-author of “A Crack in Creation,” a personal account of her research and the societal and ethical implications of gene editing.

 

Jennifer Doudna, PhD is a biochemist at the University of California, Berkeley. Her groundbreaking development of CRISPR-Cas9 - a genome engineering technology that allows researchers to edit DNA - with collaborator Emmanuelle Charpentier earned the two the 2020 Nobel Prize in Chemistry and forever changed the course of human and agricultural genomics research. She is also the founder and President of the Innovative Genomics Institute, the Li Ka Shing chancellor’s chair in Biomedical and Health Sciences, and a member of the Howard Hughes Medical Institute, Lawrence Berkeley National Lab, Gladstone Institutes, the National Academy of Sciences, and the American Academy of Arts and Sciences. She is a leader in the global public debate on the responsible use of CRISPR and has co-founded and serves on the advisory panel of several companies that use the technology in unique ways. Dr Doudna is the co-author of “A Crack in Creation,” a personal account of her research and the societal and ethical implications of gene editing.

 

Read More...
Read Less
Xuefeng Yu Photo
Xuefeng Yu
Co-founder, Chairman and CEO, CanSino Biologics Inc

Dr Yu Xuefeng is the co-founder, Chairman and CEO of CanSino Biologics Inc. He received his Master's degree in microbiology from Nankai University in 1988, and his Doctor's degree in microbiology from McGill University in Canada in 1997. In 1998, Dr Yu joined Sanofi Pasteur in Canada and successively held the positions of scientist of product development and the global director of bacterial vaccine development, where he was one of the youngest executives of the Toronto branch.

In 2009, Dr Yu returned back to China and established CanSino Biologics Inc. (CanSinoBIO), an innovative biopharmaceutical company dedicated to exploring the best solutions in the prevention of diseases through cutting edge research & development, advanced manufacturing and commercialisation of innovative vaccine products for human use worldwide. With his 30 years of experience in the development of biological products and enterprise management and operation, CanSinoBIO has currently built the pipelines of 16 vaccine candidates for 13 infectious diseases, including a globally innovative Recombinant Ebola Virus Vaccine (Adenovirus Type 5 Vector) approved in 2017, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) and the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) (MCV2) Menphecia approved in 2021.

Dr Yu also led the construction of the company's first vaccine manufacturing facility, whose design, construction and operation conform to international GMP standards. In 2019, CanSinoBIO was successfully listed on the main board of the Hong Kong Stock Exchange as well as the Sci-Tech Innovation Board of the Shanghai Stock Exchange. Led by Dr Yu and his team, CanSinoBIO will continuously launch a number of high-quality and innovative vaccines. 

Dr Yu Xuefeng is the co-founder, Chairman and CEO of CanSino Biologics Inc. He received his Master's degree in microbiology from Nankai University in 1988, and his Doctor's degree in microbiology from McGill University in Canada in 1997. In 1998, Dr Yu joined Sanofi Pasteur in Canada and successively held the positions of scientist of product development and the global director of bacterial vaccine development, where he was one of the youngest executives of the Toronto branch.

In 2009, Dr Yu returned back to China and established CanSino Biologics Inc. (CanSinoBIO), an innovative biopharmaceutical company dedicated to exploring the best solutions in the prevention of diseases through cutting edge research & development, advanced manufacturing and commercialisation of innovative vaccine products for human use worldwide. With his 30 years of experience in the development of biological products and enterprise management and operation, CanSinoBIO has currently built the pipelines of 16 vaccine candidates for 13 infectious diseases, including a globally innovative Recombinant Ebola Virus Vaccine (Adenovirus Type 5 Vector) approved in 2017, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) and the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) (MCV2) Menphecia approved in 2021.

Dr Yu also led the construction of the company's first vaccine manufacturing facility, whose design, construction and operation conform to international GMP standards. In 2019, CanSinoBIO was successfully listed on the main board of the Hong Kong Stock Exchange as well as the Sci-Tech Innovation Board of the Shanghai Stock Exchange. Led by Dr Yu and his team, CanSinoBIO will continuously launch a number of high-quality and innovative vaccines. 

Read More...
Read Less
Christina Bao073_bio_white2Mcrop (1)
Christina Bao
Co-Head of Sales & Marketing, HKEX

Ms Christina Bao, Managing Director, is currently the Co-Head of Sales & Marketing at HKEX. 

Ms Bao joined HKEX in 2016 as the Chief of Staff, reporting to the CE of HKEX. She was responsible for the planning and oversight of the Group’s strategic projects.

Prior to joining HKEX, Christina held a number of senior positions at Ping An Bank (previously at Shenzhen Development Bank, which merged with Ping An Bank in 2010) since 2001. At Shenzhen Development Bank, she served as the Chief of Staff to the Chairman and CEO from 2005 until 2010, and was responsible for the bank’s strategic projects, Investor Relations and Public Relations. After the merger and integration of the two banks, she headed Retail e-Banking, Service & Marketing, and the Retail e-Finance Strategic Business Unit for Ping An Bank.

Ms Bao received her Master of Business Administration (Finance, General) from the Peking University of Mainland China.

 

Ms Christina Bao, Managing Director, is currently the Co-Head of Sales & Marketing at HKEX. 

Ms Bao joined HKEX in 2016 as the Chief of Staff, reporting to the CE of HKEX. She was responsible for the planning and oversight of the Group’s strategic projects.

Prior to joining HKEX, Christina held a number of senior positions at Ping An Bank (previously at Shenzhen Development Bank, which merged with Ping An Bank in 2010) since 2001. At Shenzhen Development Bank, she served as the Chief of Staff to the Chairman and CEO from 2005 until 2010, and was responsible for the bank’s strategic projects, Investor Relations and Public Relations. After the merger and integration of the two banks, she headed Retail e-Banking, Service & Marketing, and the Retail e-Finance Strategic Business Unit for Ping An Bank.

Ms Bao received her Master of Business Administration (Finance, General) from the Peking University of Mainland China.

 

Read More...
Read Less
Michael Yu Photo
Michael Yu
Founder, Chairman and CEO, Innovent

Dr Michael Yu is the Founder, Chairman and Chief Executive Officer of Innovent. He is the Chairman of the Board of Chinese Antibody Association, the Vice Chairman of National Technical Committee for Standardisation of Biochemical Testing, the Vice Chairman of Professional Committee of Tumor Immunity and Tumor Biotherapy of Chinese Society of Immunology, the vice chairman of Drug Research and Development Committee of China Pharmaceutical Innovation Promotion Association. He is the Inventor of Oncorine®, Co[1]inventor and principal developer of Conbercept and TYVYT® (The above three drugs have been on the market and are the class I new drugs). And he has successively won the National Person of the Year in Innovation for Scientific and Technology in 2016, 2017 China Person of the Year in Pharmaceutical Economics, the Most Influential Person of the Year in Life Science in China in 2017 and 2019 “Dushu Lake Cup” the Most Influential Drug Research and Development Leader Reward and China Patent Gold Award in 2021 etc.

 

Dr Michael Yu is the Founder, Chairman and Chief Executive Officer of Innovent. He is the Chairman of the Board of Chinese Antibody Association, the Vice Chairman of National Technical Committee for Standardisation of Biochemical Testing, the Vice Chairman of Professional Committee of Tumor Immunity and Tumor Biotherapy of Chinese Society of Immunology, the vice chairman of Drug Research and Development Committee of China Pharmaceutical Innovation Promotion Association. He is the Inventor of Oncorine®, Co[1]inventor and principal developer of Conbercept and TYVYT® (The above three drugs have been on the market and are the class I new drugs). And he has successively won the National Person of the Year in Innovation for Scientific and Technology in 2016, 2017 China Person of the Year in Pharmaceutical Economics, the Most Influential Person of the Year in Life Science in China in 2017 and 2019 “Dushu Lake Cup” the Most Influential Drug Research and Development Leader Reward and China Patent Gold Award in 2021 etc.

 

Read More...
Read Less
Yi Shi
Yi Shi
Founder and Managing Partner, Lilly Asia Ventures

Dr Shi Yi is the Founder and Managing Partner of Lilly Asia Ventures, a leading biomedical venture capital firm with focus on China. Prior to his current role, Dr Shi worked at Eli Lilly and Company in business development licensing and corporate ventures. His education includes a Ph.D. in Biochemistry and a Master of Business Administration, both from Duke University. He also has a Bachelor of Sciences in Biology from the University of Science and Technology of China.

 

Dr Shi Yi is the Founder and Managing Partner of Lilly Asia Ventures, a leading biomedical venture capital firm with focus on China. Prior to his current role, Dr Shi worked at Eli Lilly and Company in business development licensing and corporate ventures. His education includes a Ph.D. in Biochemistry and a Master of Business Administration, both from Duke University. He also has a Bachelor of Sciences in Biology from the University of Science and Technology of China.

 

Read More...
Read Less
Silvia Chen Photo
Silvia Chen
Head of China Issuer Services, HKEX

Ms Silvia Chen is currently the Head of China Issuer Services at HKEX.  

Ms Chen joined HKEX in 2018. Prior to joining HKEX, Ms. Chen was an Executive Director at HSBC Global Banking and Capital Markets, working with Chinese enterprises on equity capital markets related matters in Hong Kong. She has led a number of landmark financing activities for Chinese and International corporates in the fields of IPO, share placement, and convertible bond issuance. Ms. Chen started her career at Merrill Lynch as an investment banking analyst, covering Retail and Consumer Products Sectors.

Ms Silvia Chen is currently the Head of China Issuer Services at HKEX.  

Ms Chen joined HKEX in 2018. Prior to joining HKEX, Ms. Chen was an Executive Director at HSBC Global Banking and Capital Markets, working with Chinese enterprises on equity capital markets related matters in Hong Kong. She has led a number of landmark financing activities for Chinese and International corporates in the fields of IPO, share placement, and convertible bond issuance. Ms. Chen started her career at Merrill Lynch as an investment banking analyst, covering Retail and Consumer Products Sectors.

Read More...
Read Less
Tian Gan
Tian Gan
CEO and CIO, ChinaAMC (HK)

Mr Gan Tian has over 15 years of investment management experience, he joined ChinaAMC (HK) in 2008 and he has served as a Portfolio Manager and Managing Director. Before joining ChinaAMC (HK), Mr Gan has worked in ChinaAMC (the parent company of ChinaAMC (HK)) as a Portfolio Manager managing the Greater China absolute return strategy in equities and a sub-portfolio of H-share in a QDII strategy. From 2005 to 2008, Mr Gan worked as a portfolio manager in Guotai Junan Assets (Asia) Ltd and was responsible for two offshore open-end China funds. Mr Gan holds Master degrees from University of Reading and University of Leicester in the United Kingdom. He also holds a Bachelor degree from Sichuan University, PRC.

Mr Gan Tian has over 15 years of investment management experience, he joined ChinaAMC (HK) in 2008 and he has served as a Portfolio Manager and Managing Director. Before joining ChinaAMC (HK), Mr Gan has worked in ChinaAMC (the parent company of ChinaAMC (HK)) as a Portfolio Manager managing the Greater China absolute return strategy in equities and a sub-portfolio of H-share in a QDII strategy. From 2005 to 2008, Mr Gan worked as a portfolio manager in Guotai Junan Assets (Asia) Ltd and was responsible for two offshore open-end China funds. Mr Gan holds Master degrees from University of Reading and University of Leicester in the United Kingdom. He also holds a Bachelor degree from Sichuan University, PRC.

Read More...
Read Less
Gary Chiu
Gary Chiu
Head of Index Strategic Research , Hang Seng Indexes Company

Mr Gary Chiu works as the Head of Index Strategic Research at Hang Seng Indexes Company Limited (“Hang Seng Indexes Company”). His role is to build Hang Seng Indexes Company’s leading position among professional investors through insightful sharing. He has 20 years’ experience as a Research Analyst covering the power utilities, renewables and infrastructure sectors in Asia-Pacific during 1996-2016, and 4 years’ experience as an Investor Relations Director in a listed company in 2016-2020 before joining Hang Seng Indexes Company.

Mr Gary Chiu works as the Head of Index Strategic Research at Hang Seng Indexes Company Limited (“Hang Seng Indexes Company”). His role is to build Hang Seng Indexes Company’s leading position among professional investors through insightful sharing. He has 20 years’ experience as a Research Analyst covering the power utilities, renewables and infrastructure sectors in Asia-Pacific during 1996-2016, and 4 years’ experience as an Investor Relations Director in a listed company in 2016-2020 before joining Hang Seng Indexes Company.

Read More...
Read Less
Sean_Wu
Sean Wu
Head of Greater China Healthcare Research, Morgan Stanley

Mr Sean Wu has been the head of Morgan Stanley’s China healthcare industry research team since September 2015. His team was ranked top 3 in six consecutive years by the Institutional Investor Poll for the Asia Healthcare and Pharmaceutical sector. He has been involved in the IPOs of Innovent, Remegen, Akeso, and other 18A Biotech companies. From August 2008 to September 2011, he was a member of the same team. Prior to rejoining the Firm, he worked for four years as the regional head for the Asia pharmaceuticals and healthcare research team at JP Morgan, covering Greater China and Korean healthcare companies. Sean has also worked at Rodman & Renshaw, a boutique investment bank, covering US biotechnology companies. Mr Wu has a bachelor of science degree in biotechnology from Fudan University, a PhD in basic biomedical sciences from New York University, and an MBA from the University of Chicago.

Mr Sean Wu has been the head of Morgan Stanley’s China healthcare industry research team since September 2015. His team was ranked top 3 in six consecutive years by the Institutional Investor Poll for the Asia Healthcare and Pharmaceutical sector. He has been involved in the IPOs of Innovent, Remegen, Akeso, and other 18A Biotech companies. From August 2008 to September 2011, he was a member of the same team. Prior to rejoining the Firm, he worked for four years as the regional head for the Asia pharmaceuticals and healthcare research team at JP Morgan, covering Greater China and Korean healthcare companies. Sean has also worked at Rodman & Renshaw, a boutique investment bank, covering US biotechnology companies. Mr Wu has a bachelor of science degree in biotechnology from Fudan University, a PhD in basic biomedical sciences from New York University, and an MBA from the University of Chicago.

Read More...
Read Less
Iris Wang Photo
Iris Wang
Partner, OrbiMed

Iris (Ting) Wang, CFA, is a Partner for OrbiMed. Prior to joining OrbiMed, Ms Wang was a Director at Credit Suisse and Head of Asia and China Healthcare Research team. Previously, Ms Wang was a management consultant at McKinsey and A.T. Kearney, focusing on China healthcare and supply chain management. Ms Wang is an M.B.A. degree holder from Columbia Business School, and graduated from the Value Investing Program with Dean’s Honor in 2011. She also holds two B.S. degrees in biological science and economics from Peking University.

Iris (Ting) Wang, CFA, is a Partner for OrbiMed. Prior to joining OrbiMed, Ms Wang was a Director at Credit Suisse and Head of Asia and China Healthcare Research team. Previously, Ms Wang was a management consultant at McKinsey and A.T. Kearney, focusing on China healthcare and supply chain management. Ms Wang is an M.B.A. degree holder from Columbia Business School, and graduated from the Value Investing Program with Dean’s Honor in 2011. She also holds two B.S. degrees in biological science and economics from Peking University.

Read More...
Read Less
Winnie Photo
Winnie Han
Senior Vice President, Global Issuer Services, HKEX

Ms Winnie Han is the Senior Vice President of Global Issuer Services at HKEX. Her key focus is on market development, introducing and promoting the HKEX IPO platform to potential issuers, investors, governments, associations and intermediaries.

Prior to her current role, Ms Han has over 10 years of experience in China A-share investment banking coverage at UBS and Credit Suisse. She holds a China A-share Sponsor Representatives Qualification and a Certified Public Accountant Qualification of China (non-practicing).

 Ms Han received her Master’s degree from Peking University and Bachelor’s degree from Xiamen University.

Ms Winnie Han is the Senior Vice President of Global Issuer Services at HKEX. Her key focus is on market development, introducing and promoting the HKEX IPO platform to potential issuers, investors, governments, associations and intermediaries.

Prior to her current role, Ms Han has over 10 years of experience in China A-share investment banking coverage at UBS and Credit Suisse. She holds a China A-share Sponsor Representatives Qualification and a Certified Public Accountant Qualification of China (non-practicing).

 Ms Han received her Master’s degree from Peking University and Bachelor’s degree from Xiamen University.

Read More...
Read Less
Bonnie Y Chan
Bonnie Y Chan
Head of Listing, HKEX

Bonnie Y Chan is Head of Listing at the Hong Kong Exchanges and Clearing Limited.

Ms Chan has over 25 years of experience in legal and financial services. She started her career in private legal practice, worked in a number of investment banks and was a partner at Davis Polk & Wardwell before assuming her current role.

She was Head of IPO of the Listing Division at the Hong Kong Exchanges and Clearing Limited between 2007 and 2010.

Ms Chan has served on various public service bodies, including the Financial Services Development Council, the Inland Revenue Board, the Standing Committee of Company Law Reform and the Disciplinary Panel of the HKICPA.

Ms Chan graduated from the University of Hong Kong in 1991 and Harvard Law School in 1993. She is admitted as a solicitor in Hong Kong and an attorney at law in New York State.

 

Bonnie Y Chan is Head of Listing at the Hong Kong Exchanges and Clearing Limited.

Ms Chan has over 25 years of experience in legal and financial services. She started her career in private legal practice, worked in a number of investment banks and was a partner at Davis Polk & Wardwell before assuming her current role.

She was Head of IPO of the Listing Division at the Hong Kong Exchanges and Clearing Limited between 2007 and 2010.

Ms Chan has served on various public service bodies, including the Financial Services Development Council, the Inland Revenue Board, the Standing Committee of Company Law Reform and the Disciplinary Panel of the HKICPA.

Ms Chan graduated from the University of Hong Kong in 1991 and Harvard Law School in 1993. She is admitted as a solicitor in Hong Kong and an attorney at law in New York State.

 

Read More...
Read Less
Franck Le Deu Photo
Franck Le Deu
Senior Partner, McKinsey & Company (HK)

Mr Franck Le Deu is a Senior Partner at the Hong Kong Office of McKinsey & Company, where he co-leads the Asia Pharma and MedTech practice.

Mr Le Deu joined McKinsey & Company in 2001 in New Jersey, moved to Shanghai in 2005 and to Hong Kong in 2016. He has over 20 years of experience advising leading biopharmaceuticals and MedTech multinationals, as well as Chinese biotechs on strategic issues, including entry strategy, franchise or brand strategy, partnership/business development, agile organisation transformation, digital and analytics, as well as portfolio roadmap and R&D.

He has co-authored multiple papers on the China market, including “China Healthcare Reform – Moving beyond Reading of the Tea Leaves, 2009”, “Healthcare in China – Entering Uncharted Waters, 2012”, “In Search of New Growth Models for Big Pharma in China, 2013” and most recently “Building Bridges to Innovation, 2014 to 2020”, “Managing China’s Growing Oncology Burden, 2020”or “How COVID-19 Changes the Game for Biopharma in China, 2020”. He also publishes a blog on LinkedIn focused on the development of the China biopharma market. 

Mr Le Deu is also a frequent speaker at leading industry conferences, including DeviceChina 2012, PharmAsia Summit 2013, CHIC 2015 and keynote speeches at the BioCentury China Healthcare Summit from 2014 to 2016 and the Goldman Sachs Asia Healthcare Forum since 2017.

Mr Le Deu, is a French citizen, holds an MBA degree from Northwestern University (Kellogg), and a Master in Management from AUDENCIA. He is a member of BayHelix (since 2014), and a board member of the Asian Fund for Cancer Research (AFCR – not for profit organisation).

Mr Franck Le Deu is a Senior Partner at the Hong Kong Office of McKinsey & Company, where he co-leads the Asia Pharma and MedTech practice.

Mr Le Deu joined McKinsey & Company in 2001 in New Jersey, moved to Shanghai in 2005 and to Hong Kong in 2016. He has over 20 years of experience advising leading biopharmaceuticals and MedTech multinationals, as well as Chinese biotechs on strategic issues, including entry strategy, franchise or brand strategy, partnership/business development, agile organisation transformation, digital and analytics, as well as portfolio roadmap and R&D.

He has co-authored multiple papers on the China market, including “China Healthcare Reform – Moving beyond Reading of the Tea Leaves, 2009”, “Healthcare in China – Entering Uncharted Waters, 2012”, “In Search of New Growth Models for Big Pharma in China, 2013” and most recently “Building Bridges to Innovation, 2014 to 2020”, “Managing China’s Growing Oncology Burden, 2020”or “How COVID-19 Changes the Game for Biopharma in China, 2020”. He also publishes a blog on LinkedIn focused on the development of the China biopharma market. 

Mr Le Deu is also a frequent speaker at leading industry conferences, including DeviceChina 2012, PharmAsia Summit 2013, CHIC 2015 and keynote speeches at the BioCentury China Healthcare Summit from 2014 to 2016 and the Goldman Sachs Asia Healthcare Forum since 2017.

Mr Le Deu, is a French citizen, holds an MBA degree from Northwestern University (Kellogg), and a Master in Management from AUDENCIA. He is a member of BayHelix (since 2014), and a board member of the Asian Fund for Cancer Research (AFCR – not for profit organisation).

Read More...
Read Less
Amit Kakar
Amit Kakar
Senior Partner and Head of Asia, Novo Holdings Asia

Dr Amit Kakar joined Novo Holdings Asia in August 2020 as Head of Asia to lead investments and partnerships across the region, focusing primarily on the markets in China, South East Asia and India.

Dr Kakar has more than 25 years of healthcare experience with several senior management roles across the globe and having worked in India, China, Singapore, Denmark and the USA. Previously, he workedwith Everlife Asia based in Singapore as Head of M&A and Business Development, and with the Avenue Capital Group as Head of Healthcare Investments for Asia and with GE Healthcare in several senior leadership positions.

Dr Kakar is a Medical Doctor with a postgraduate degree in Radiation and Nuclear Medicine from Tata Memorial Hospital and Cancer Centre in Mumbai, India.

Dr Amit Kakar joined Novo Holdings Asia in August 2020 as Head of Asia to lead investments and partnerships across the region, focusing primarily on the markets in China, South East Asia and India.

Dr Kakar has more than 25 years of healthcare experience with several senior management roles across the globe and having worked in India, China, Singapore, Denmark and the USA. Previously, he workedwith Everlife Asia based in Singapore as Head of M&A and Business Development, and with the Avenue Capital Group as Head of Healthcare Investments for Asia and with GE Healthcare in several senior leadership positions.

Dr Kakar is a Medical Doctor with a postgraduate degree in Radiation and Nuclear Medicine from Tata Memorial Hospital and Cancer Centre in Mumbai, India.

Read More...
Read Less
Ying Yang
Ying Yang
Vice President and Worldwide Business Development Asia Lead, Pfizer Investment Co., Ltd.

Dr Yang Ying has 20 years of pharmaceutical industry experience spanning across commercial, development and manufacturing. Dr Yang is currently leading China Strategy and Asia Business Development. In 2020, she successfully led and completed the strategic collaboration with Cstone, Cansino and LianBio. In the past 5 years, she was based in China as the Strategy & Business Development Lead, and Chief of Staff for the Greater China Region. Before that, Dr Yang worked in the Pfizer US Headquarters for 12 years. Dr Yang holds a Ph.D. in Industrial Engineering & Management Sciences from Northwestern University, and a Bachelor’s degree in Chemistry from Fudan University in Shanghai.

Dr Yang Ying has 20 years of pharmaceutical industry experience spanning across commercial, development and manufacturing. Dr Yang is currently leading China Strategy and Asia Business Development. In 2020, she successfully led and completed the strategic collaboration with Cstone, Cansino and LianBio. In the past 5 years, she was based in China as the Strategy & Business Development Lead, and Chief of Staff for the Greater China Region. Before that, Dr Yang worked in the Pfizer US Headquarters for 12 years. Dr Yang holds a Ph.D. in Industrial Engineering & Management Sciences from Northwestern University, and a Bachelor’s degree in Chemistry from Fudan University in Shanghai.

Read More...
Read Less
NisaQiming
Nisa Leung
Managing Partner, Qiming Venture Partners

Ms Nisa Leung is a Managing Partner of Qiming Venture Partners, and is leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages investment in over 380 companies.

Ms Leung currently sits on the board of Zai Lab, Venus MedTech, CanSino Biologics and New Horizon Health among others.

Ms Leung has been recognised by the Forbes Global 100 VC Midas List in 2019, 2020 and 2021 and named amongst the Best Women VCs List by Forbes China (#2 in 2021, #3 in 2018).

Ms Leung earned her M.B.A. from Stanford Graduate School of Business and B.S. from Cornell University. She is currently a visiting lecturer at Harvard Law School and Advisory Council Member of the Stanford Graduate School of Business. She is a committee member on Innovation, Technology and Re-industrialisation and serves as an independent non-executive director of the Hong Kong Exchanges and Clearing Limited.

Ms Nisa Leung is a Managing Partner of Qiming Venture Partners, and is leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages investment in over 380 companies.

Ms Leung currently sits on the board of Zai Lab, Venus MedTech, CanSino Biologics and New Horizon Health among others.

Ms Leung has been recognised by the Forbes Global 100 VC Midas List in 2019, 2020 and 2021 and named amongst the Best Women VCs List by Forbes China (#2 in 2021, #3 in 2018).

Ms Leung earned her M.B.A. from Stanford Graduate School of Business and B.S. from Cornell University. She is currently a visiting lecturer at Harvard Law School and Advisory Council Member of the Stanford Graduate School of Business. She is a committee member on Innovation, Technology and Re-industrialisation and serves as an independent non-executive director of the Hong Kong Exchanges and Clearing Limited.

Read More...
Read Less
Michael Chan Photo
Michael Chan
Senior Vice President, Global Issuer Services, HKEX

Mr Michael Chan is a Senior Vice President of Global Issuer Services who heads the international IPO and issuer marketing efforts for HKEX. Mr Chan mainly focuses on market development work promoting the Hong Kong listing platform and origination work attracting international and biotechnology companies to list in Hong Kong. In addition to leading the marketing efforts globally and working closely with prospects and constituents, Mr Chan often speaks and serves as panellist and keynote speaker at major conferences and events locally and internationally. Prior to his current role, Mr Chan has worked at the Listing Division of HKEX for 8 years covering areas of compliance, corporate governance, regulatory and IPO-related matters.

Prior to joining HKEX, Mr Chan has worked at various financial institutions in corporate finance and business development. Michael has more than 19 years of experience in financial services and regulatory work.

 

 

Mr Michael Chan is a Senior Vice President of Global Issuer Services who heads the international IPO and issuer marketing efforts for HKEX. Mr Chan mainly focuses on market development work promoting the Hong Kong listing platform and origination work attracting international and biotechnology companies to list in Hong Kong. In addition to leading the marketing efforts globally and working closely with prospects and constituents, Mr Chan often speaks and serves as panellist and keynote speaker at major conferences and events locally and internationally. Prior to his current role, Mr Chan has worked at the Listing Division of HKEX for 8 years covering areas of compliance, corporate governance, regulatory and IPO-related matters.

Prior to joining HKEX, Mr Chan has worked at various financial institutions in corporate finance and business development. Michael has more than 19 years of experience in financial services and regulatory work.

 

 

Read More...
Read Less